By leveraging the company’s innovative development platform, MapLight has already brought two novel therapeutics into the clinic, with more on the horizon. Focused on solutions that serve populations currently struggling with either no treatment options or limited options with significant safety liabilities, MapLight’s initial therapeutics are aimed at safely targeting key symptoms of Autism Spectrum Disorder, Schizophrenia, Alzheimer’s Disease, Parkinson’s Disease, and Dyskinesias.
Learn more about our Alzheimer’s Disease Psychosis studies »4 of 6
Learn more about our Alzheimer’s Disease Psychosis studies »5 of 6
Learn more about our Dyskinesia studies »6 of 6
MapLight's focus on indications with high unmet medical need
Autism Spectrum Disorder